Ascendis Pharma A/S(ASND)

POST229.230.000.00%19:30 EDT

229.23+6.54+2.94%

CommunityCommunity
NewsNews
ProfileProfile
AnnouncementsAnnouncements

- RBC Capital Sticks to Its Buy Rating for Ascendis Pharma (ASND)
  TIPRANKS · 10-09 09:47
  RBC Capital Sticks to Its Buy Rating for Ascendis Pharma (ASND)
- What Does Ascendis Pharma (ASND) Gain From Its CNP Patent Settlement?
  Simply Wall St. · 10-07
  What Does Ascendis Pharma (ASND) Gain From Its CNP Patent Settlement?
- Ascendis Says Pooled PaTH Forward/PaTHway Data Show TransCon PTH Normalizes Bone Measures over 5 Years in Hypoparathyroidism
  Reuters · 10-06
  Ascendis Says Pooled PaTH Forward/PaTHway Data Show TransCon PTH Normalizes Bone Measures over 5 Years in Hypoparathyroidism
- BioMarin Signs Global Patent License Deal with Ascendis for TransCon CNP Products
  Reuters · 10-01
  BioMarin Signs Global Patent License Deal with Ascendis for TransCon CNP Products
- Barclays Reaffirms Their Buy Rating on Ascendis Pharma (ASND)
  TIPRANKS · 09-30
  Barclays Reaffirms Their Buy Rating on Ascendis Pharma (ASND)
- Analysts’ Opinions Are Mixed on These Healthcare Stocks: Ascendis Pharma (ASND), Lakefront Biotherapeutics (LKFT) and 10x Genomics (TXG)
  TIPRANKS · 09-28
  Analysts’ Opinions Are Mixed on These Healthcare Stocks: Ascendis Pharma (ASND), Lakefront Biotherapeutics (LKFT) and 10x Genomics (TXG)
- Ascendis Pharma Price Target Maintained with a $300.00/Share by Cantor Fitzgerald
  Dow Jones · 09-28
  Ascendis Pharma Price Target Maintained with a $300.00/Share by Cantor Fitzgerald
- Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (VRTX), Ascendis Pharma (ASND) and Charles River Labs (CRL)
  TIPRANKS · 09-16
  Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (VRTX), Ascendis Pharma (ASND) and Charles River Labs (CRL)
- Ascendis Pharma A/S Stock (ASND) Moved Down by 12.08% on Sep 15: What Signal Does It Send?
  TradingKey · 09-16
  Ascendis Pharma A/S Stock (ASND) Moved Down by 12.08% on Sep 15: What Signal Does It Send?
- Movement Alert｜Ascendis Pharma A/S Falls 12.23% in Regular Trading, Termination of Novo Nordisk Obesity Drug Collaboration Triggers Selloff
  Market Focus · 09-16
  Movement Alert｜Ascendis Pharma A/S Falls 12.23% in Regular Trading, Termination of Novo Nordisk Obesity Drug Collaboration Triggers Selloff
- Ascendis Pharma Tumbles on Novo Nordisk Collab Termination
  Reuters · 09-15
  Ascendis Pharma Tumbles on Novo Nordisk Collab Termination
- Ascendis Pharma falls -12.1%
  TIPRANKS · 09-15
  Ascendis Pharma falls -12.1%
- Sector Update: Healthcare
  MT Newswires Live · 09-15
  Sector Update: Healthcare
- Ascendis Pharma Regains Rights to Weight-Loss Technology; Share Buyback Approved
  Dow Jones · 09-15
  Ascendis Pharma Regains Rights to Weight-Loss Technology; Share Buyback Approved
- Ascendis Pharma to regain rights to TransCon technology-based products
  TIPRANKS · 09-15
  Ascendis Pharma to regain rights to TransCon technology-based products
- Ascendis Pharma announces $400M share repurchase plan
  TIPRANKS · 09-15
  Ascendis Pharma announces $400M share repurchase plan
- Ascendis Pharma a/S - to Regain Exclusive Rights to Transcon Technology in Metabolic and Cardiovascular Diseases
  THOMSON REUTERS · 09-15
  Ascendis Pharma a/S - to Regain Exclusive Rights to Transcon Technology in Metabolic and Cardiovascular Diseases
- Press Release: Ascendis Announces Planned $400 Million Share Repurchase Program
  Dow Jones · 09-15
  Press Release: Ascendis Announces Planned $400 Million Share Repurchase Program
- Ascendis Pharma SVP & PAO Mads Bodenhoff Disposes of 3,000 Common Shares Worth $810,570
  Reuters · 09-10
  Ascendis Pharma SVP & PAO Mads Bodenhoff Disposes of 3,000 Common Shares Worth $810,570
- Ascendis Pharma announces data from reACHin Trial
  TIPRANKS · 09-10
  Ascendis Pharma announces data from reACHin Trial
Company Profile
Company Name
Ascendis Pharma A/S
Market
NASDAQ
Establishment Date
- -
Employees
- -
Office Location
- -
Website
http://www.ascendispharma.com
Zip Code
- -
Phone
- -
Fax
- -
Introduction
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company also develops TransCon Growth Hormone for treating pediatric GHD, adult GHD, and turner syndrome; TransCon Parathyroid Hormone for adult patients with hypoparathyroidism; and TransCon C-type natriuretic peptide for achondroplasia. In addition, it is developing TransCon toll like receptors 7/8 agonist for intratumoral delivery; and TransCon IL-2 ß/? for systemic delivery. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.
- 09-08
  Proposed Sale Of Securities
  Form 144 - Report of proposed sale of securities
  Form 144 - Report of proposed sale of securities
- 09-02
  Proposed Sale Of Securities
  Form 144 - Report of proposed sale of securities
  Form 144 - Report of proposed sale of securities
- 08-14
  Beneficial Ownership Change
  Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
  Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
- 05-15
  Beneficial Ownership Change
  Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
  Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
- 05-15
  Beneficial Ownership Change
  Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
  Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
- 05-11
  Proposed Sale Of Securities
  Form 144 - Report of proposed sale of securities
  Form 144 - Report of proposed sale of securities
- 05-07
  Beneficial Ownership Change
  Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
  Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
- 05-07
  Beneficial Ownership Change
  Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors
  Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors
- 05-06
  Beneficial Ownership Change
  Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
  Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
- 03-09
  Proposed Sale Of Securities
  Form 144 - Report of proposed sale of securities
  Form 144 - Report of proposed sale of securities
- 03-06
  Proposed Sale Of Securities
  Form 144 - Report of proposed sale of securities
  Form 144 - Report of proposed sale of securities
- 03-05
  Proposed Sale Of Securities
  Form 144 - Report of proposed sale of securities
  Form 144 - Report of proposed sale of securities
- 03-05
  Proposed Sale Of Securities
  Form 144 - Report of proposed sale of securities
  Form 144 - Report of proposed sale of securities
- 03-05
  Proposed Sale Of Securities
  Form 144 - Report of proposed sale of securities
  Form 144 - Report of proposed sale of securities
- 03-04
  Proposed Sale Of Securities
  Form 144 - Report of proposed sale of securities
  Form 144 - Report of proposed sale of securities

1D
5D
Day
Week
Month

Loading ...

High

233.96

Open

225.08

Volume%

0.96

Low

223.96

222.69

T/O Rate

1.24%

To The Moon

Ascendis Pharma A/S(ASND)

Company Profile

Most Discussed